WASHINGTON, March 16 -- The U.S. Environmental Protection Agency has released the following public communication dated March 3, 2025, from GreenLatinos: * * * To: Marcy Card Existing Chemicals Risk Management Division Office of Pollution Prevention and Toxics Environmental Protection Agency 1200 Pennsylvania Ave. NW Washington, DC 20460-000195812 Re: Comments on the Draft Scope of the Risk Evaluation Under the Toxic Substances Control Act (TSCA) for Vinyl Chloride; Docket Number: EPA-HQ-OPPT-2018-0448 * * * To Ms. Card, GreenLatinos  more ST

WASHINGTON, March 16 -- The U.S. Department of the Treasury Internal Revenue Service has released the following public communication dated Feb. 27, 2025, from Forvis Mazars LLP, Charlotte, North Carolina: * * * To: Internal Revenue Service CC:PA:01:PR (REG-105479-18) Room 5203 P.O. Box 7604, Ben Franklin Station Washington, DC 20044 Re: Previously Taxed Earnings and Profits and Related Basis Adjustments * * * Dear Sir or Madam: On December 2, 2024, the Department of the Treasury (Treasury) and the Internal Revenue Service (IRS) issued more ST

WASHINGTON, March 14 -- Sen. Edward J. Markey, D-Massachusetts, issued the following news release: * * * Markey, Whitehouse Lead EPW Democrats in Demanding Zeldin Halt Political Witch Hunt Against Money-Saving Clean Energy Investments Administrator Zeldin is manipulating facts as a pretext to terminate a congressionally appropriated and legally obligated program that would lower household energy costs, spur economic development, and reduce pollution Washington, (March 14, 2025) - Today, Senator Edward J. Markey (D-Mass.) and Senator Sheldo more PR

WASHINGTON, March 15 (TNSFR) -- Sterling Pharma USA LLC, based in Cary, North Carolina, has applied to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of several Schedule I controlled substances. The company is seeking approval to produce tetrahydrocannabinols, psilocybin, dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and psilocyn. According to the DEA filing, Sterling Pharma USA intends to manufacture these substances to support internal research efforts and for sale to customers conducting pre-clinic more PR